Skip to main content

Table 5 Risk associated of either DCIS or invasive cancer for each feature

From: Mammographic texture and risk of breast cancer by tumor type and estrogen receptor status

Feature DCIS Invasive    ER– ER+   
OR (95% CI) OR (95% CI) p value* p het** OR (95% CI) OR (95% CI) p value* p het**
N case/N control 254/1659 908/1659    116/1291 746/1291   
FD_TH_75 0.87 (0.74–1.01) 0.87 (0.78–0.96) 0.010 0.98 0.84 (0.67–1.06) 0.88 (0.79–0.99) 0.048 0.72
Energy 0.88 (0.76–1.02) 0.88 (0.80–0.96) 0.011 0.93 0.85 (0.69–1.05) 0.86 (0.78–0.95) 0.009 0.90
Entropy 1.18 (1.02–1.38) 1.13 (1.03–1.25) 0.010 0.60 1.16 (0.93–1.44) 1.15 (1.03–1.28) 0.024 0.96
FD_TH_70 0.85 (0.72–1.00) 0.87 (0.79–0.97) 0.015 0.75 0.84 (0.67–1.06) 0.89 (0.79–1.00) 0.085 0.64
FD_TH_80 0.90 (0.77–1.04) 0.89 (0.81–0.98) 0.034 0.90 0.85 (0.68–1.05) 0.89 (0.80–1.00) 0.066 0.64
FD_TH_10 1.19 (1.04–1.38) 1.09 (0.99–1.19) 0.022 0.21 1.03 (0.84–1.26) 1.06 (0.96–1.18) 0.479 0.75
Kurtosis 0.86 (0.73–1.00) 0.90 (0.81–0.99) 0.032 0.58 0.98 (0.78–1.22) 0.91 (0.81–1.01) 0.216 0.53
FD_TH_65 0.84 (0.71–0.99) 0.89 (0.80–0.99) 0.035 0.49 0.83 (0.65–1.06) 0.91 (0.81–1.03) 0.170 0.46
FD_Minkowski 0.90 (0.74–1.08) 0.86 (0.77–0.97) 0.042 0.71 0.77 (0.59–1.01) 0.89 (0.78–1.01) 0.063 0.32
Busyness 1.15 (1.00 –1.33) 1.09 (1.00–1.19) 0.053 0.46 0.92 (0.75–1.14) 1.09 (0.99–1.21) 0.128 0.12
Homogeneity 1.05 (0.90–1.22) 1.13 (1.03–1.24) 0.042 0.36 1.06 (0.86–1.31) 1.12 (1.01–1.24) 0.091 0.62
Dissimilarity 0.96 (0.83–1.12) 0.89 (0.81–0.98) 0.057 0.35 0.95 (0.77–1.17) 0.89 (0.81–0.99) 0.110 0.61
FD_TH_60 0.85 (0.71–1.02) 0.9 (0.8–1.01) 0.077 0.56 0.9 (0.69–1.15) 0.92 (0.81–1.04) 0.348 0.85
FD_TH_85 0.92 (0.79–1.06) 0.91 (0.83–1) 0.130 0.98 0.89 (0.72–1.09) 0.91 (0.82–1.01) 0.173 0.77
FD_TH_15 1.2 (1.04–1.39) 1.06 (0.97–1.16) 0.034 0.09 0.96 (0.78–1.18) 1.05 (0.95–1.16) 0.572 0.43
  1. Results are presented as odds ratio (OR) and 95% confidence interval (CI) per 1 standard deviation in normalized feature after adjustment for age, family history, percent density, and study
  2. *p value refers to two degrees of freedom to test for evidence of association with ductal carcinoma in situ (DCIS) or invasive cancer
  3. **Heterogeneity p value (p het) to test for differences in effect between tumor subgroups
  4. ER estrogen receptor